(Q37832287)

24 August 2017

1 reference

title

Pharmacogenomics of antipsychotics efficacy for schizophrenia (English)

1 reference

24 August 2017

0 references

1 reference

1

Ramón Cacabelos

1 reference

24 August 2017

Ryota Hashimoto

2

1 reference

24 August 2017

Masatoshi Takeda

series ordinal

3

1 reference

24 August 2017

publication date

1 February 2011

1 reference

Psychiatry and Clinical Neurosciences

24 August 2017

published in

1 reference

24 August 2017

volume

65

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

3-19

1 reference

Pharmacogenetics and drug development: the path to safer and more effective drugs

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Antipsychotic-induced paroxysmal perceptual alteration in a patient with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Four cases of venous thromboembolism associated with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Atypical antipsychotics in the treatment of delirium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Behavioral and psychological symptoms of dementia and medical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Management of behavioral and psychological symptoms of dementia in long-term care facilities in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Genomics and the future of pharmacotherapy in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Pharmacogenetics and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

PM frequencies of major CYPs in Asians and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

CYP2C9 allelic variants: ethnic distribution and functional significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Cytochrome P450 in the brain; a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Cytochrome P450 polymorphisms and response to antipsychotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Pharmacogenetics and the serotonin system: initial studies and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Genomewide association study of movement-related adverse antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Measuring the value of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Regulation of cytochrome P450 (CYP) genes by nuclear receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Dopamine D4 receptor subtypes and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1819.2010.02168.X

10.1111/J.1440-1819.2010.02168.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference